Clinical Trial Update: A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma. [Phase 2]

View source ↗

Summary

Phase II trial evaluating stereotactic body radiotherapy with concurrent anti-PD1 therapy in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-PD1

Snippet

Sponsor: University Hospital, Ghent | Conditions: Melanoma | Phase 2 | Status: COMPLETED